AstraZeneca Pharma India Limited – Corporate Governance and Market Update (8 August 2026)

AstraZeneca Pharma India Limited, a subsidiary of AstraZeneca Pharmaceuticals AB, has announced key corporate events and provided a brief market snapshot for the day.

Board of Directors Meeting

On 4 August 2026, the company notified the Bombay Stock Exchange (BSE) that a Board of Directors meeting will take place on 10 August 2026. The agenda will include the consideration and approval of the company’s 2025‑26 annual report, financial results, and related corporate actions.

Shareholder Meeting

In a notice dated 6 August 2026, the company informed shareholders that a general meeting is scheduled for 1 September 2026. The notice, addressed to shareholders and filed with the BSE, invites participants to review the company’s financial statements, dividend policy and other matters presented in the 2025‑26 annual report.

Annual Report 2025‑26

The company released its annual report for the fiscal year 2025‑26 on 6 August 2026. The report provides a comprehensive overview of the company’s financial performance, operating highlights and governance framework. It is available for download on the BSE portal and serves as a key document for investors and regulators.

Market Performance (as of 4 August 2026)

  • Close price: INR 8 108,50
  • 52‑week high: INR 9 849,50 (02 November 2025)
  • 52‑week low: INR 7 551,50 (05 April 2026)
  • Market capitalisation: INR 205 262 503 936
  • Price‑earnings ratio: 109.12

The stock remains listed on the National Stock Exchange of India under the ticker AZN and is also traded on the BSE.

Contextual Notes

AstraZeneca Pharma India Limited operates in the pharmaceutical sector, focusing on cardiovascular, renal, metabolic, immunological, oncology, rare‑disease, and respiratory medicines. The company’s portfolio includes flagship products such as TAGRISSO, Lynparza, ENHERTU, IMFINZI, Zoladex, Symbicort, and Fasenra, and it offers clinical‑trial services. Strategic collaborations include a joint effort with Leica Biosystems and Daiichi Sankyo for an immunohistochemistry assay and image‑analysis algorithm targeting the TROP2 NMR biomarker in non‑small‑cell lung cancer.

The board and shareholder meetings announced today are routine governance events, reflecting the company’s adherence to regulatory disclosure requirements and its commitment to transparent communication with investors.